Here are the S-3 shelf registrations from CalciMedica, Inc. (CALC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow CALC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CALC filings page.
CalciMedica, Inc. has filed a resale registration covering up to 56,020,287 shares of common stock for selling stockholders. These include 14,938,370 issued shares, 3,735,059 shares issuable upon exercise of pre-funded warrants, 18,673,429 shares issuable upon exercise of Series A warrants, and 18,673,429 shares issuable upon exercise of Series B warrants, all tied to a June 23, 2026 private placement of 18,673,429 units.
The company is not selling shares itself and will receive no proceeds from stockholder resales, but would receive cash upon warrant exercises at $0.0001 per pre-funded warrant share, $0.8033 per Series A Warrant share (or $0.8032 per related pre-funded warrant), and $1.00 per Series B Warrant share (or $0.9999 per related pre-funded warrant). Shares outstanding were 30,736,401 as of July 9, 2026; this is a baseline figure, not the amount being offered.
Warrants and pre-funded warrants are subject to beneficial ownership limits up to 19.99%. CalciMedica is a clinical-stage biopharmaceutical company developing CRAC channel inhibitors, including Auxora and CM5480, and qualifies as a smaller reporting company on Nasdaq under the symbol CALC.
CalciMedica, Inc. has filed a shelf registration prospectus to offer, from time to time, up to $125,000,000 of common stock, preferred stock, debt securities and/or warrants.
The filing states offerings will be made in one or more offerings with specific terms provided in prospectus supplements; sales are described as issuer offerings and proceeds are for the issuer’s general corporate purposes. The company’s common stock trades on Nasdaq under the symbol CALC (last reported sale $0.507 per share on March 2, 2026).